2021年12月17日金曜日

シノバックからもダメダメのお知らせで3歳児にまで接種しまくってた中国は今後滅亡の危機に

2021年12月13日月曜日

抗原原罪(OAS)はmRNAワクチンのみならずAZ等ウイルスベクター系やシノバックやスプートニックV等不活性化ワクチンでも発生する



2021年12月16日木曜日

闇雲なワクチン集団接種という愚策により地球上に44億人以上のオミクロン株を宿す感染宿主(コンプロマイズド・ホスト)という名の免疫劣等種爆誕へ

2021年12月16日木曜日

Hong Kong researchers find that two doses of China’s Sinovac vaccine are inadequate against Omicron.

A new study looking at blood samples from people who received two doses of a Covid-19 vaccine made by the Chinese pharmaceutical company Sinovac suggested that the vaccine would be unable to prevent an infection of the new, highly infectious Omicron variant.

The research, which analyzed the blood of 25 people vaccinated with Sinovac, is the latest sign of the new challenge Omicron presents as it spreads across the world. The scientists from the University of Hong Kong found that, in laboratory experiments, none of the 25 samples produced sufficient antibodies to block the variant from invading cells. The researchers said it was not yet clear whether a third shot of Sinovac would improve the results.

The studies are preliminary, and antibody levels do not give a complete picture of a person’s immune response. It is unclear whether the Sinovac vaccine can fend off severe disease or death from Omicron, but it most likely offers some protection.

Sinovac said in a statement Wednesday that while two doses of its vaccine were much less effective against Omicron, three doses might prevent infection with the variant.

The study also examined blood from 25 people vaccinated with the Pfizer-BioNTech vaccine and found less than one-quarter of the subjects produced antibodies that could neutralize Omicron. These results were consistent with what other studies have found.

The researchers advised the public in Hong Kong to get a third dose of vaccine as soon as possible, though they did not specify which kind.

If the results are accurate, they could spell particular trouble for China, where the vaccine is commonly used. China has vaccinated more than 1 billion of its citizens, mostly with Chinese vaccines, but has relied largely on strict lockdowns and quarantines to curb the spread of the virus. Other studies have also found disappointing results with Sinopharm, the other major vaccine in China.

In recent weeks, Chinese officials have indicated that the country’s vaccination levels are approaching what they said would be required for herd immunity. However, Sinovac’s weakness against the new variant, two cases of which were detected this week in two Chinese cities, could signal that the country’s lockdowns and closed borders will persist.

Beginning in September, parts of the country began to offer booster shots, and now the extra shot is widely available. This month a top Chinese official called for an acceleration in plans to give booster shots to older adults. In Tianjin, where one of China’s two confirmed Omicron cases was found, state media wrote in a Wednesday article that “there should be no delay in getting boosters.”

Even so, far fewer people have had boosters. As of Dec. 10, 120 million people in China have had a third vaccine dose, far short of the 1.16 billion who have had two, according to state media.

https://www.nytimes.com/2021/12/15/world/asia/omicron-hong-kong-study.html


 

China to start vaccinating children to age 3 as cases spread

October 25, 2021

TAIPEI, Taiwan (AP) — Children as young as 3 will start receiving COVID-19 vaccines in China, where 76% of the population has been fully vaccinated and authorities are maintaining a zero-tolerance policy toward outbreaks.

China becomes one of the very few countries in the world to start vaccinating children that young against the virus. Cuba, for one, has begun a vaccine drive for children as young as 2. The U.S. and many European countries allow COVID-19 shots down to age 12, though the U.S. is moving quickly toward opening vaccinations to 5- to 11-year-olds.

Local city and provincial level governments in at least five Chinese provinces issued notices in recent days announcing that children ages 3 to 11 will be required to get their vaccinations.

The expansion of the vaccination campaign comes as parts of China take new clampdown measures to try to stamp out small outbreaks. Gansu, a northwestern province heavily dependent on tourism, closed all tourist sites Monday after finding new COVID-19 cases. Residents in parts of Inner Mongolia have been ordered to stay indoors because of an outbreak there.

The National Health Commission reported that 35 new cases of local transmission had been detected over the past 24 hours, four of them in Gansu. An additional 19 cases were found in the Inner Mongolia region, with others scattered around the country.

China has employed lockdowns, quarantines and compulsory testing for the virus throughout the pandemic and has largely stamped out cases of local infection while fully vaccinating 1.07 billion people out of a population of 1.4 billion.

In particular, the government is concerned about the spread of the more contagious delta variant by travelers and about having a largely vaccinated public ahead of the Beijing Olympics in February. Overseas spectators already have been banned from the Winter Games, and participants will have to stay in a bubble separating them from people outside.

China’s most widely used vaccines, from Sinopharm and Sinovac, have shown efficacy in preventing severe disease and transmission of the virus, based on public data. But the protection they offer against the delta variant has not been answered definitively, although officials say they remain protective.

Hubei, Fujian and Hainan provinces all issued provincial level notices alerting new vaccination requirements, while individual cities in Zhejiang province and Hunan province have also issued similar announcements.

China in June had approved two vaccines — Sinopharm’s from the Beijing Institute of Biological Products and Sinovac — for children ages 3 to 17, but it has only been vaccinating those 12 and older. In August, regulators approved another, Sinopharm’s from the Wuhan Institute of Biological Products.

After the vaccines received domestic approval for children in China, foreign governments began giving the shots to children in their own countries. Cambodia uses both Sinovac and Sinopharm’s shots in children 6 to 11. Regulators in Chile approved Sinovac for children as young as 6. In Argentina, regulators approved the Sinopharm vaccine for children as young as age 3.

Many developing countries left out of the race to get shots from Western pharmaceutical companies like Pfizer and Moderna bought Chinese vaccines. China has shipped more than 1.2 billion doses as of September, according to its Ministry of Foreign Affairs.

Even with widespread domestic and global use, not every parent is reassured about the vaccine, citing less publicly available data on the shots.

Wang Lu, who lives in the southern city of Fuzhou in Fujian province, said she isn’t particularly rushing to get her 3-year-old son vaccinated. “I’m just not very clear on the vaccine’s safety profile, so I don’t really want to get him vaccinated, at the very least, I don’t want to be the first,” Wang said.

Sinovac started an efficacy trial with 14,000 child participants across multiple countries in September. Its approval in China was based on smaller phase 1 and phase 2 trials. Sinopharm’s Beijing shot was also approved based on smaller phase 1 and phase 2 trials. These were published later in peer-reviewed journals.

Other parents said they weren’t concerned, given that many other people had already gotten the shot.

Wu Cong, a mom of a 7-year old, said her daughter’s school in Shanghai hadn’t yet notified them of any vaccinations.

“I think this isn’t too different from the flu vaccine, there’s already been so many people vaccinated, so I don’t have too many worries,” said Wu.

 https://apnews.com/article/coronavirus-pandemic-lifestyle-business-beijing-travel-4680b533429a7e3e75c6f99745b3664b



アイヤー!(爆wwwwwwwwwwwwwww 

3 件のコメント:

匿名 さんのコメント...

シノバックで支那爆(死)wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww

ミネ さんのコメント...

一人っ子政策なんて無駄でしかなったねww

匿名 さんのコメント...

Global Times
https://www.globaltimes.cn › page
WHO extends coverage of SINOVAC's COVID-19 vaccine for 3-year-olds ...
2 日前 —...among people aged between 3-11 who had received two shots of COVID-19 vaccines stayed at 0.01 percent after accepting a third one; the rate decreased from 0.03 percent to 0.01 percent among those aged 13-19. Meanwhile, the fatality rate among people aged 60-69 vaccinated with two shots decreased from about 1.7 percent to 0.5 percent after a third shot.